16 results about "Infectious agent" patented technology

The application discloses a modified crRNA, a light-controlled nucleic acid detection system, a kit and application, and belongs to the cross field of biotechnology, intelligent sensing and molecular diagnosis. In view of the technical defects of strong target sequence dependence and high ultraviolet irradiation requirement of the existing light-controlled CRISPR technology, the application innovatively introduces a photosensitive protection group 6-nitropiperidin oxymethyl (NPOM) at a specific key node of a stem loop skeleton of crRNA maintaining conformation. In the constant temperature amplification stage, preferred double-site cooperative modification can transiently inhibit RNP complex assembly to realize target non-interference enrichment; subsequently, only 10 mW / cm 2 of extremely low intensity ultraviolet light irradiation for 30 seconds can restore the crRNA conformation and activate the trans cleavage. The preferred technical scheme of the application can eliminate the target sequence limitation, realizes a detection limit of as low as 2 copies in a single reaction tube, and the result can be obtained within 15 minutes. The system is widely applicable to rapid diagnosis of infectious agents, high-specificity typing of single nucleotide polymorphism and portable intelligent molecular diagnosis terminal.

Disclosed herein are methods and systems for rapid detection of microorganisms, such as bacteria, in a sample. Also disclosed is a genetically modified bacteriophage comprising an indicator gene encoding one subunit of an indicator protein. The specificity of the bacteriophage allows detection of specific target bacteria, and the indicator signal can be amplified to optimize assay sensitivity.

In the present invention, cyclic dinucleotides or their compositions are used as biological response modifiers to enhance the immune response of subjects with deficient immune systems, with a low or absent response to vaccine antigens, or with a deficient immune response to pathogens. The formulations of the present invention are capable of modifying the biological response in such a way as to eliminate the lack of response, resulting in the development of a high-avid immune response that prevents disease caused by infectious agents, particularly viruses with the ability to evade immune surveillance mechanisms and, consequently, suppress the induction of an effective, high-avid adaptive response.The present invention also comprises cyclic dinucleotide formulations, which can be administered alone, in combination with other biological response modifiers, or in vaccine formulations with antigens. The proposed invention further includes a method for preventing or treating acute respiratory infections, preventing disease severity, and blocking transmission by inducing an immune response at the point of entry (nasopharyngeal mucosa), preventing or reducing person-to-person transmission of pathogens / viruses in preventive vaccine formulations, as well as in formulations used for prophylaxis before and after exposure to acute respiratory infections.

A method for operating infection-control air-conditioning according to a concentration of airborne infectious agents according to the present disclosure may comprise the steps of: collecting air quality data of a target space in which one or more infection-control air-conditioning devices are disposed; calculating prediction data associated with a concentration of airborne infectious agents in the target space on the basis of the air quality data; and controlling an operating condition of the infection-control air-conditioning devices on the basis of the prediction data.

Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species within the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and / or strains of infectious agents. Also provided are specific fusion proteins, nucleic acid molecules encoding such fusion proteins and methods of using nanoparticles of the invention to vaccinate individuals.

A device that receives non-sterile air subjects the airflow to one or more sterilizing agents or conditions and then expels it through a nozzle or set of nozzles, forming a jet of air or set of air jets directed toward the surface of a living being's head, so that the sterilized airflow envelops it. The result is that a) the living being breathes air free of one or more infectious agents and b) the air jet forms an air curtain that protects it from inhaling infectious agents that may be surrounding it.

This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and influenza virus infection and inducing effective coronavirus and influenza virus antigen-specific immune responses such as antibody and / or T cell responses.

A synthetic DNA molecule comprising one segment encoding a tumor neoantigen or an epitope from an infectious agent under the control of a promoter for the transcription into a corresponding RNA molecule and a segment for the translation of the translated RNA molecule into a peptide.

A device for determining presence or absence of infection due to an infectious agent is described. The device comprises a sample receiving zone configured to receive a liquid sample from a subject suspected of having an infection due to an infectious agent, the sample receiving zone positioned to distribute the sample along a first fluid flow path to a first label zone and along a second fluid flow path to a second label zone. Test lines in each fluid flow path capture a mobile detectable species as an indicator of presence or absence of the infectious agent. The device also comprises a reference line positioned in the one of the fluid flow paths. The bidirectional fluid flow paths emanate from a common sample zone and provide an efficient approach to detection and differentiate two species as indicators of the same infectious agent or as indicators of two different infectious agents.

Disclosed herein are methods and systems for rapid detection of microorganisms such as bacteria in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene encoding one subunit of an indicator protein. The specificity of the bacteriophage allows detection of a particular bacteria of interest and an indicator signal may be amplified to optimize assay sensitivity.

The present disclosure relates to obtaining Foley catheters and double-J catheters that exhibit antibacterial properties and prevent stone formation by means of coating the surfaces of urinary catheters used in the healthcare sector with multiple film layers comprising groups containing gallic acid so as to impart antibacterial properties and stone-formation-preventing effectiveness. It is intended in particular to prevent the ascending transmission of bacteria from the female or male genital region to the bladder with the aid of the catheter during urethral catheter insertion, as well as stone formation due to stasis arising from the slowing of flow and turbulent flow associated with ureteral stents inserted in cases of stricture. It is also intended to prevent the occurrence of damage that may form in the urinary tract due to oxidative stress and inflammation triggered either by infection in the surrounding tissues or by mechanical pressure caused by the stone. Effectiveness is achieved by coating the surfaces of the catheters / stents applied to the urinary tract with film layers of gallic acid, which is effective in all the aforementioned adverse conditions in preventing stone formation and is effective against infectious agents, and which has antioxidant and anti-inflammatory effects.

This invention provides an anti-infection protection structure for peritoneal dialysis catheters, including a peritoneal dialysis catheter insertion cannula, a conical connecting tube connected to the insertion cannula, a conical connecting tube connected to a cannula retaining ring, a cannula retaining ring connected to an antibacterial protective catheter sheath, and an antibacterial protective catheter sheath connected to a sterile protective cap. Through the synergistic effect of multiple components such as the antibacterial protective catheter sheath, sterile protective cap, anti-infection isolation ring, antibacterial coating sleeve, and antibacterial filter element, this invention effectively inhibits bacterial growth and reproduction, reducing the possibility of external infectious agents entering the peritoneal dialysis catheter, thereby significantly reducing the risk of infection for patients during peritoneal dialysis. The antibacterial filter element, composed of an activated carbon filter, a graphene filter layer, and a filter membrane layer, effectively removes harmful substances, improves the purity of the fluid entering the peritoneal dialysis catheter, and thus enhances the safety of peritoneal dialysis.

Described is a location interaction tracking system. The system includes a server storing user information including location information and a plurality of user computing devices coupled to the server. The server may be programmed to receive and store location information from a first user computing device of the plurality of user computing devices and aggregate and anonymize the location information as historical paths of travel, wherein the plurality of user computing devices is programmed to send location information at predetermined intervals. A user may use a user computing device to mark himself as a confirmed case for an infectious agent. The system may then label the aggregated, anonymized location information of the user computing device as confirmed and determine what other user computing devices have crossed within a predetermined distance of the confirmed user during a predetermined past time period and notify the users crossing paths with the confirmed user.

This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection, and / or RSV infection and inducing effective coronavirus, influenza virus, and / or RSV antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject (i) a bivalent RNA vaccine encoding peptides or proteins comprising epitopes of SARS-CoV-2 spike proteins (S proteins) and (ii) a tetravalent RNA vaccine encoding peptides or proteins comprising epitopes of hemagglutinin (HA), for inducing an immune response against coronavirus S proteins, in particular S proteins of SARS-CoV-2, and influenza proteins, in particular HA proteins of type A and type B influenza viruses, in the subject.

Embodiments of the present disclosure are directed to systems and methods for collection and analysis of environmental air dust (EAD) within an individually ventilated cage rack (IVR) environment for detecting pathogens. The method includes collection of an EAD sample by a collection media, isolation of a plurality of nucleic acids (e.g., RNA and / or DNA) representative of one or more infectious agents from the EAD sample, optional reverse transcription of RNA to cDNA if the isolated nucleic acids contain RNA, amplification of the cDNA and / or DNA (e.g., by polymerase chain reaction (PCR)), and assay interpretation. Optionally, the EAD sample may be analyzed with one or more other sample types (e.g., fecal pellets, oral swabs, body swabs, tissue, etc.) to improve detection of low-copy organisms.